| Autor: |
Nurhidayati, Dwi Yuni, Yuliati, Yuliati, Fahrinda, Almira, Raras, Tri Yudhani Mardining, Sujuti, Hidayat, Prawiro, Sumarno Reto |
| Předmět: |
|
| Zdroj: |
AIP Conference Proceedings; 2023, Vol. 2634 Issue 1, p1-8, 8p |
| Abstrakt: |
Tuberculosis is a global epidemic, one of the top 10 causes of death in the world. One of the potent anti-tuberculosis drugs used in the treatment of tuberculosis is Rifampicin. Meanwhile, Ag38kDa recombinant protein contains 2 Mtb-specific B cell epitopes and is believed to be the most potent immunogen. The purpose of this study is to compare Rifampicin with recombinant protein antibody Ag38kDa and the combination of both in stimulating the response of T-lymphocytes by observing the percentage of CD4+ and CD8+ cells that can be a breakthrough for the treatment of active tuberculosis. This study involved several treatment groups, the antibody recombinant protein Ag38kDa group, the Rifampicin group, and the combination group. All treatment groups were compared with positive controls. All treatment groups were examined by flow cytometry, and SPSS statistics were adopted to calculate the results. The average percentage of CD4+ cells treated with Rifampicin increases compared to the control (0.00<0.05). For CD8+, there is a significant increase in all treatment groups compared to controls (0.00<0.05). The increase of CD4+ and CD8+ aid the bacteria eradication process that infects cells and inhibits the growth and spread of mycobacteria in tuberculosis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
